BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 15827127)

  • 1. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome.
    Sloand EM; Mainwaring L; Fuhrer M; Ramkissoon S; Risitano AM; Keyvanafar K; Lu J; Basu A; Barrett AJ; Young NS
    Blood; 2005 Aug; 106(3):841-51. PubMed ID: 15827127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy.
    Sloand EM; Melenhorst JJ; Tucker ZC; Pfannes L; Brenchley JM; Yong A; Visconte V; Wu C; Gostick E; Scheinberg P; Olnes MJ; Douek DC; Price DA; Barrett AJ; Young NS
    Blood; 2011 Mar; 117(9):2691-9. PubMed ID: 21097671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset.
    Fozza C; Contini S; Galleu A; Simula MP; Virdis P; Bonfigli S; Longinotti M
    Exp Hematol; 2009 Aug; 37(8):947-55. PubMed ID: 19409953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities.
    Sloand EM; Kim S; Fuhrer M; Risitano AM; Nakamura R; Maciejewski JP; Barrett AJ; Young NS
    Blood; 2002 Dec; 100(13):4427-32. PubMed ID: 12393649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles.
    Molldrem JJ; Jiang YZ; Stetler-Stevenson M; Mavroudis D; Hensel N; Barrett AJ
    Br J Haematol; 1998 Sep; 102(5):1314-22. PubMed ID: 9753062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro deprivation of CD8(+)CD57(+)T cells promotes the malignant growth of bone marrow colony cells in patients with lower-risk myelodysplastic syndrome.
    Zheng Z; Qianqiao Z; Qi H; Feng X; Chunkang C; Xiao L
    Exp Hematol; 2010 Aug; 38(8):677-84. PubMed ID: 20394797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell receptor Vβ skewing frequently occurs in refractory cytopenia of childhood and is associated with an expansion of effector cytotoxic T cells: a prospective study by EWOG-MDS.
    Aalbers AM; van den Heuvel-Eibrink MM; Baumann I; Beverloo HB; Driessen GJ; Dworzak M; Fischer A; Göhring G; Hasle H; Locatelli F; De Moerloose B; Noellke P; Schmugge M; Stary J; Yoshimi A; Zecca M; Zwaan CM; van Dongen JJ; Pieters R; Niemeyer CM; van der Velden VH; Langerak AW
    Blood Cancer J; 2014 May; 4(5):e209. PubMed ID: 24786393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptotic cells and clonally expanded cytotoxic T cells in bone marrow trephines of patients with myelodysplastic syndrome.
    Pülhorn H; Herrmann M; Harms H; Jung A; Baumann I
    Histopathology; 2012 Aug; 61(2):200-11. PubMed ID: 22690734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorescence in situ hybridization of progenitor cells obtained by fluorescence-activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes.
    Saitoh K; Miura I; Takahashi N; Miura AB
    Blood; 1998 Oct; 92(8):2886-92. PubMed ID: 9763574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.
    Bouscary D; De Vos J; Guesnu M; Jondeau K; Viguier F; Melle J; Picard F; Dreyfus F; Fontenay-Roupie M
    Leukemia; 1997 Jun; 11(6):839-45. PubMed ID: 9177438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal cell lineage involvement in myelodysplastic syndromes studied by fluorescence in situ hybridization and morphology.
    Bernell P; Jacobsson B; Nordgren A; Hast R
    Leukemia; 1996 Apr; 10(4):662-8. PubMed ID: 8618444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.
    Chamuleau ME; Westers TM; van Dreunen L; Groenland J; Zevenbergen A; Eeltink CM; Ossenkoppele GJ; van de Loosdrecht AA
    Haematologica; 2009 Apr; 94(4):496-506. PubMed ID: 19229054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process.
    Epperson DE; Nakamura R; Saunthararajah Y; Melenhorst J; Barrett AJ
    Leuk Res; 2001 Dec; 25(12):1075-83. PubMed ID: 11684279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes.
    Abbas HA; Reville PK; Jiang X; Yang H; Reuben A; Im JS; Little L; Sinson JC; Chen K; Futreal A; Garcia-Manero G
    Front Immunol; 2021; 12():659625. PubMed ID: 33912187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.
    Fozza C; Corda G; Barraqueddu F; Virdis P; Contini S; Galleu A; Isoni A; Dore F; Angelucci E; Longinotti M
    Leuk Res; 2015 Sep; 39(9):957-63. PubMed ID: 26209197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma.
    Bagot M; Echchakir H; Mami-Chouaib F; Delfau-Larue MH; Charue D; Bernheim A; Chouaib S; Boumsell L; Bensussan A
    Blood; 1998 Jun; 91(11):4331-41. PubMed ID: 9596682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent Abnormal Clones in Myelodysplastic Syndrome Marrow Originate from Cells at a Pluripotent Stem Level and Maintain Their Early Differentiation Potency.
    Qi H; Qingxia Z; Xiao L; Lingyun W; Feng X; Zheng Z; Chunkang C
    Cancer Invest; 2015; 33(8):369-77. PubMed ID: 26135215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients.
    Yabe M; Medeiros LJ; Tang G; Wang SA; P Patel K; Routbort M; Bhagat G; Bueso-Ramos CE; Jorgensen JL; Luthra R; Chen W; Muzzafar T; Kanagal-Shamanna R; Khoury JD; Daneshbod Y; Davanlou M; Li S; Young KH; Miranda RN
    Hum Pathol; 2016 Apr; 50():109-17. PubMed ID: 26997444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression.
    Kochenderfer JN; Kobayashi S; Wieder ED; Su C; Molldrem JJ
    Blood; 2002 Nov; 100(10):3639-45. PubMed ID: 12393644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined immunophenotyping and DNA in situ hybridization to study lineage involvement in patients with myelodysplastic syndromes.
    Kibbelaar RE; van Kamp H; Dreef EJ; de Groot-Swings G; Kluin-Nelemans JC; Beverstock GC; Fibbe WE; Kluin PM
    Blood; 1992 Apr; 79(7):1823-8. PubMed ID: 1558974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.